Chronic Kidney Disease (CKD) Anemia Market (2026-2036)

The growth of this market is mainly driven by the arrival of orally administered hypoxia-inducible factor prolyl hydroxylase inhibitors alongside injectable erythropoiesis-stimulating agents, by the size of the non-dialysis chronic kidney disease population relative to the dialysis population and the absence of an approved oral agent for it in the United States, by intravenous iron formulations that permit full replacement in one or two visits rather than a course of infusions, by the expansion of dialysis capacity and of diagnosed chronic kidney disease in Asia-Pacific, and by separate transitional payment that allows a new dialysis drug to earn reimbursement outside the bundled rate for a defined period. Anemia management is a lifelong requirement in advanced chronic kidney disease, so demand is driven by the number of patients under treatment rather than by episode volumes, and the composition of the market shifts between drug classes more than the total expands.

However, factors such as the inclusion of anemia management for dialysis patients within a bundled per-treatment payment that is not increased when a new drug enters it, the expiry of transitional separate payment after a defined period, boxed warnings on both the erythropoiesis-stimulating agent and the hypoxia-inducible factor inhibitor classes for death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access, the absence of any demonstrated improvement in quality of life, fatigue or patient well-being on either class, and price erosion from biosimilar epoetins are expected to restrain the growth of this market to some extent. Labelling on both classes directs use of the lowest dose sufficient to reduce the need for red blood cell transfusions, so the clinical objective is transfusion avoidance within a narrow hemoglobin range rather than correction of anemia, and that objective caps the price a payer will fund for any agent in this market.

The erythropoiesis-stimulating agent class labelling, which carries a boxed warning that these agents increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence, records that in controlled trials patients experienced greater risks for death, serious adverse cardiovascular reactions and stroke when administered these agents to target a hemoglobin level greater than 11 g/dL, states that no trial has identified a hemoglobin target level, dose or dosing strategy that does not increase these risks, directs use of the lowest dose sufficient to reduce the need for red blood cell transfusions, and indicates the class for anemia due to chronic kidney disease in patients on dialysis and patients not on dialysis while stating that it has not been shown to improve quality of life, fatigue or patient well-being, and the clinical objective it sets is narrower than the name of the market suggests. Treatment is directed at reducing the need for red blood cell transfusions at the lowest effective dose within a hemoglobin range below 11 g/dL, not at correcting anemia or at making a patient feel better, since the labelling states that no improvement in quality of life, fatigue or patient well-being has been shown. A manufacturer entering this market is therefore competing on dosing convenience, administration route and tolerability rather than on a superior clinical outcome, and the price a payer will fund is anchored to the cost of the transfusions avoided rather than to a patient benefit that can be demonstrated.

The Vafseo label, which carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access, states that no trial has identified a hemoglobin target level, dose or dosing strategy that does not increase these risks, directs use of the lowest dose sufficient to reduce the need for red blood cell transfusions within a hemoglobin range of 10 g/dL to 11 g/dL, indicates the product for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and states that it has not been shown to improve quality of life, fatigue or patient well-being and is not indicated for patients with anemia due to chronic kidney disease who are not on dialysis carries the same warning and the same limitation. An oral agent therefore offers route of administration rather than efficacy or safety advantage over an injectable one, which is a genuine benefit in a population that would otherwise require a clinic visit for each dose but not a benefit that supports a premium against a class already carrying the same warning. The indication is also restricted to adults who have been receiving dialysis for at least three months, and the label states expressly that the product is not indicated for anemia due to chronic kidney disease in patients who are not on dialysis, which excludes the larger patient population from the approved use.

Anemia management for patients on dialysis in the United States falls within a bundled per-treatment payment, and the transitional drug add-on payment adjustment under the Medicare end-stage renal disease prospective payment system, which provides separate payment to dialysis facilities for certain new renal dialysis drugs at 100 percent of average sales price, or at 100 percent of wholesale acquisition cost or the manufacturer invoice where average sales price is unavailable, for two years where the drug treats a condition within an existing functional category and until sufficient claims data are available for rate setting where it does not, after which a drug in an existing functional category moves to a post-transitional add-on payment adjustment and the base rate is not changed is the mechanism through which a new drug earns reimbursement outside that bundle for a limited period. The transitional add-on period for Vafseo, which runs from 1 January 2025 through 31 December 2026, so the separate payment for the only hypoxia-inducible factor inhibitor available to dialysis patients in that market ends at the close of the first year of this forecast period, after which the product moves to a post-transitional add-on adjustment with the base rate unchanged. A manufacturer in that position is competing for a share of a fixed payment already made to the facility rather than for additional money, and the facility has a direct financial reason to prefer the lowest-cost agent that meets the hemoglobin target.

The precedent for what follows is already established within the same payment system. Calcimimetics received transitional separate payment and then ceased to do so, becoming payable through the base rate with eligibility for outlier payments from 1 January 2021, which is the pattern a dialysis anemia drug can expect once its transitional period expires. Oral-only phosphate binders entered transitional payment from 1 January 2025 on the same terms. A manufacturer planning entry into the dialysis setting is therefore planning for a defined window of separate payment followed by competition inside a bundle, and the commercial case has to be made within that window rather than across the life of the product.

The non-dialysis population is where the unmet need and the uncertainty both sit. Patients with chronic kidney disease who are not yet on dialysis outnumber those who are by a wide margin, their anemia is managed in nephrology clinics and physician offices rather than in dialysis centres, and payment for their treatment comes through ordinary pharmacy and medical benefit channels rather than through a bundled dialysis rate. Erythropoiesis-stimulating agents are indicated for this population but require injection and carry the class warning, and no oral agent is approved for it in the United States, so the therapeutic gap is route of administration rather than drug class. This is the fastest-growing patient segment in the market and the one in which an approval would change the forecast most.

Iron replacement sits alongside both classes rather than competing with them, since iron deficiency limits the response to any agent that stimulates erythropoiesis and has to be corrected before or during treatment. Newer intravenous formulations permit a full replacement dose in one or two administrations rather than a course of smaller infusions, which reduces clinic visits for non-dialysis patients and chair time for dialysis patients, and oral ferric citrate offers iron replacement with phosphate binding in a single product. The segment grows with the number of patients under anemia management rather than with the share of any particular stimulating agent, which makes it the most stable part of this market.

Long-acting agents are expected to hold the largest share within this segment in 2026, since less frequent administration suits both the dialysis schedule and the non-dialysis clinic visit and supports a higher price per dose. Short-acting epoetins retain a substantial share where dosing flexibility within a narrow hemoglobin band is preferred and where price is the governing consideration. Biosimilar epoetins are projected to register the highest CAGR, taking share on price in settings where anemia management sits inside a bundled or capitated payment and the facility retains the saving, and in emerging markets where the lower price brings treatment to patients who would otherwise receive transfusion alone. Share gained by biosimilars reduces segment value while increasing the number of patients treated, so this is the one segment in which patient volume and segment value move in opposite directions across the forecast period.

Intravenous iron is expected to account for the largest share within this segment in 2026, reflecting reliable delivery of a full replacement dose, administration alongside a dialysis session at no additional visit cost, and the limited absorption and gastrointestinal tolerability of oral iron in advanced chronic kidney disease. Newer formulations delivering a full replacement dose in one or two administrations hold the growing part of that share because they remove clinic visits for non-dialysis patients. Oral iron is projected to register the highest CAGR, driven by earlier anemia management in stage 3 and stage 4 patients who are not attending a clinic for infusion and by ferric citrate, which combines iron replacement with phosphate binding in a single product and is therefore funded against two indications. Within intravenous iron, the newer high-dose formulations carry the premium position while older iron sucrose and iron dextran products compete on acquisition cost inside bundled settings.